- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00056966
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Participants in this study have a hematologic malignancy (a disorder in the bone marrow that affects the body's ability to create blood) that might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor) from a family member or nearly identical matched donor. The donor may either be a matched sibling, a mismatched family member, or an unrelated person.
Usually these patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells that remain in the body. However, this group of patients have a high risk of developing possibly life-threatening treatment-related side effects such as infections, damage to vital organs such as lungs, liver, kidney and heart, as well as graft versus host disease (GVHD).
Instead of the high dose chemotherapy and radiotherapy usually given before a transplant, this research study uses a new pre-transplant combination of three drugs, Fludarabine, Anti-CD45 and CAMPATH-1H with low dose radiotherapy. Fludarabine is a chemotherapy drug while Anti-CD45 and CAMPATH-1H are antibodies against certain types of blood cells, including those which are causing this disease. CAMPATH-1H is particularly important because it stays active in the body for a long time after it is given, which means it may work longer to prevent GVHD symptoms. Anti-CD45 may help in eradicating residual malignant cells. All these agents also help in preventing rejection of donor stem cells. This study is designed to give a less intense chemotherapy and radiotherapy, so that the life-threatening toxicities of conventional high dose chemotherapy and radiotherapy regimen can be reduced, while maintaining the ability to cure cancer.
Study Overview
Status
Conditions
Detailed Description
CAMPATH-1H will be given as a daily IV infusion for three days. Fludarabine will be given as a daily IV infusion for four days. Anti-CD45 will be given as a daily IV infusion for 4 days. Patients will then receive radiotherapy (also known as Total Body Irradiation or TBI) for one day. A summary of the treatment follows:
- Day - 8: CAMPATH-1H and Fludarabine
- Day - 7: CAMPATH-1H and Fludarabine
- Day - 6: CAMPATH-1H and Fludarabine
- Day - 5: Anti-CD45 and Fludarabine
- Day - 4: Anti-CD45
- Day - 3: Anti-CD45
- Day - 2: Anti-CD45
- Day - 1: TBI
- Day 0: Stem Cell Infusion (transplant)
To help prevent the body from developing GVHD, patients will also receive the drug FK506, starting two days before the transplant and continuing for at least one month.
Both the CAMPATH-1H and the Anti-CD45 can cause allergic reactions so patients will be given drugs to help prevent those reactions before receiving daily doses.
To see how CAMPATH-1H works in patients with hematologic malignancies, some patients will be asked to participate in pharmacokinetic studies. For this, approximately 13 blood samples will be taken from the central line scheduled before each infusion on Day -8 to Day -6, daily thereafter until Day 0, and then approximately once per week on days 7, 14, 21 and 28 post transplant. No more than 5 teaspoonfuls total will be drawn.
To see how Anti-CD45 works in patients with hematologic malignancies some patients will be asked to participate in pharmacokinetic studies. Approximately 22 blood samples will be taken from the central line scheduled before, during and after each infusion and after the end of the last infusion of Anti-CD45. No more than 10 teaspoonfuls total will be drawn over the course of the four anti-CD45 infusions.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with one of the following high risk diseases needing allogeneic hemopoietic stem cell transplantation:
Acute myeloid leukemia either a) Primary refractory, or b) Beyond first complete remission(CR1), or c) In CR1 with high risk of relapse
Acute lymphoblastic leukemia either a) Primary refractory, or b) Beyond first complete remission(CR1), or c) In CR1 with high risk of relapse
Chronic myeloid leukemia, either a) Accelerated phase, or b) Blast crisis, or c) Chronic phase and not achieving major cytogenetic response despite standard therapy
Chronic lymphocytic leukemia, either a) Primary refractory, or b) Beyond first complete remission(CR1),
Non Hodgkin's lymphoma, either a) Primary refractory, or b) Beyond first complete remission(CR1)
Hodgkin's disease, either a) Primary refractory, or b) Beyond first complete remission(CR1),
Myelodysplastic syndrome with IPSS score > 0. (Appendix A)
Myeloproliferative disorders (with the exclusion of chronic myeloid leukemia) a) Primary Myelofibrosis with Lile score of 1 or 2 (Appendix B) b) Polycythemia Vera or Essential Thrombocythemia transformed to AML or Myelofibrosis and PV "spent phase"
Multiple Myeloma with stage II or III disease
Severe aplastic anemia
Conditions that increase Treatment Related Mortality (need one or more to be eligible):
Greater or equal to 35 years of age;
Ejection Fraction of less than 50%;
DLCO less than 50% or FEV1/FVC < 80% of predicted value;
Diabetes Mellitus;
Renal insufficiency (serum creatinine abnormal);
Hepatic dysfunction-transaminases, or alkaline phosphatase, or bilirubin twice the upper limit of normal;
Prior recent history of systemic fungal infection;
Multiple prior treatment regimens (equal to or more than 3);
Significant Grade III or IV neurologic, cardiac, pulmonary, renal or hepatic toxicity from previous treatment;
Prior Autologous or Allogeneic Stem Cell transplantation;
- Available Healthy Donor without any contraindications for donation. 5/6 or 6/6 related or unrelated donor (molecular typing for DRB1);
- Patient and/or responsible person able to understand and sign consent
Exclusion Criteria:
Pregnant and lactating women, or women unwilling to use contraception.
HIV positive patient
Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater)
Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater)
Child's class C cirrhosis
Unstable cerebral vascular disease or recent hemorrhagic stroke (less than 6 months)
Patients with known allergy to rat serum products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
recipients of HLA matched sibling transplants
|
400ug/kg Day-5 through Day-2
Day -8 through Day -6 Dosed per Institutional SOP
Other Names:
Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Other Names:
Day-8 through Day-5 30 mg/m2
Day-1 single dose 450 cGy
Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg).
When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
|
Experimental: 2
recipients of unrelated or mismatched family donor transplants
|
400ug/kg Day-5 through Day-2
Day -8 through Day -6 Dosed per Institutional SOP
Other Names:
Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Other Names:
Day-8 through Day-5 30 mg/m2
Day-1 single dose 450 cGy
Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg).
When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess safety and feasibility of monoclonal abs directed to CD45 and CD52 antigens, Fludarabine and low dose TBI, as a non-myeloablative preparatory regimen for allo HSCT. This will be determined by 100d Non-relapse mortality and 100d Graft rejection
Time Frame: 100 days post transplant
|
100 days post transplant
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To obtain a preliminary estimate of the efficacy of this therapy as defined by: Complete remission at day 100 and One-year disease free survival.
Time Frame: 100 days and 1 year post transplant
|
100 days and 1 year post transplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Malcolm K Brenner, MD, Baylor College of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Hematologic Neoplasms
- Hematologic Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Calcineurin Inhibitors
- Fludarabine
- Tacrolimus
- Alemtuzumab
Other Study ID Numbers
- 12472 (Stanford IRB)
- ACHE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
Clinical Trials on ANTI-CD45
-
University Health Network, TorontoCompleted
-
University Hospital, AngersFrench Innovative Leukemia OrganisationUnknownAdult Acute Lymphoblastic LeukemiaFrance
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedMyelodysplastic Syndromes | LeukemiaUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...TerminatedFanconi Anemia | Severe Aplastic AnemiaUnited States
-
Baylor College of MedicineThe Methodist Hospital Research InstituteTerminatedInherited Metabolic Storage DiseasesUnited States
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineTerminatedSevere Combined Immunodeficiency Disease | Severe Primary Immunodeficiency Disorder | Undefined T Cell Deficiency Disorder | Wiskott-Aldrick SyndromeUnited States
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of Medicine; University of...TerminatedFANCONI ANEMIAUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Terminated
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedNasopharyngeal Cancer | EBV InfectionsUnited States